Adverum Biotechnologies Completes IND Amendment And Prepares To Initiate The Phase 2 LUNA Trial Of ADVM-022 In Wet AMD

– Cash runway extended into 2025 due to corporate restructuring to prioritize the clinical development of ADVM-022 and provide additional resources beyond anticipated one-year topline results of the Phase 2 LUNA trial

– LUNA trial will enroll up to 72 patients and examine two dose levels of ADVM-022 along with four new enhanced prophylactic steroid regimens

– Anticipate dosing the first patient with ADVM-022 in the third quarter of 2022